<DOC>
	<DOCNO>NCT01227824</DOCNO>
	<brief_summary>The purpose trial ass non-inferior antiviral activity GSK1349572 50 mg daily versus RAL 400mg twice daily 48 week ; non-inferiority also test Week 96 . Both GSK1349572 RAL give combination fixed-dose dual NRTI therapy ( ABC/3TC TDF/FTC ) . This study conduct HIV-1 infect ART-naïve adult subject .</brief_summary>
	<brief_title>A Trial Comparing GSK1349572 50mg Once Daily Raltegravir 400mg Twice Daily</brief_title>
	<detailed_description>ING113086 Phase 3 randomize , double-blind , double dummy , active-controlled , multicenter , study conduct approximately 788 HIV-1 infect ART-naïve subject . Subjects randomize 1:1 one follow treatment arm : 1 . GSK1349572 50 mg daily ( approximately 394 subject ) + fixed-dose dual NRTI therapy ( either ABC/3TC TDF/FTC ) OR 2 . 400 mg RAL twice daily ( approximately 394 subject ) + fixed-dose dual NRTI therapy ( either ABC/3TC TDF/FTC ) Analyses conducted 48 week 96 week . Subjects randomize receive GSK1349572 successfully complete 96 week treatment continue access GSK1349572 study either locally available , long continue derive clinical benefit . ViiV Healthcare new sponsor study , GlaxoSmithKline process update system reflect change sponsorship</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Screening plasma HIV1 RNA ≥1000 c/mL Antiretroviralnaïve ( ≤ 10 day prior therapy antiretroviral agent follow diagnosis HIV1 infection ) Ability understand sign write informed consent form Willingness use approve method contraception avoid pregnancy ( woman child bear potential ) Age equal great 18 year Women pregnant breastfeeding ; Active Center Disease Prevention Control ( CDC ) Category C disease Moderate severe hepatic impairment Anticipated need HCV therapy study Allergy intolerance study drug component drug class Malignancy within past 5 year Treatment HIV1 immunotherapeutic vaccine within 90 day Screening Treatment radiation therapy , cytotoxic chemotherapeutic agent immunomodulator within 28 day Screening Exposure agent document activity HIV1 vitro experimental vaccine drug within 28 day first dose study medication Primary viral resistance Screening result Verified Grade 4 laboratory abnormality ALT &gt; 5 xULN ALT ≥ 3xULN bilirubin ≥ 1.5xULN ( &gt; 35 % direct bilirubin ) ; Estimated creatinine clearance &lt; 50 mL/min Recent history ( ≤3 month ) upper low gastrointestinal bleed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>integrase inhibitor</keyword>
	<keyword>HIV Infection</keyword>
	<keyword>raltegravir</keyword>
	<keyword>GSK1349572</keyword>
</DOC>